Search Videos and More
Showing 1 - 8 of 8 results
News
Innovative Endometrial Cancer Research Offers Fresh Promise for Patients
For the past decade, new cases of endometrial (uterine) cancer have been on the rise in the United States. The past few years, however, have brought a more promising rise: A new generation of drugs and drug combinations that are improving the outlook for patients with the disease.
News
Gordon J. Freeman, PhD, Recognized with 2024 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
Gordon J. Freeman, PhD, of Dana-Farber Cancer Institute, will receive the 2024 AACR-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology from the American Association for Cancer Research (AACR).
News
Potent Oral Agent Acting as Immunotherapy and Targeted Treatment Produces High Response Rate in Certain Patients
A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies, a clinical trial conducted by researchers at Dana-Farber Cancer Institute and around the world has found.
News
Three-Drug Combination Slows Progression of Advanced Kidney Cancer
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
News
Study Finds That Risk of Adverse Side Effects From Cancer Immunotherapy is Higher in Patients with Certain Inherited Genetic Variations
Even as they've revolutionized cancer treatment, drugs known as immune checkpoint inhibitors can produce a range of adverse, immune-related side effects. In a new study, scientists at Dana-Farber Cancer Institute identify, for the first time, inherited genetic variations that place patients at high risk for these complications.
News
Bispecific Antibodies Continue the Promise of Immunotherapy
Until recently, when adults with acute lymphocytic leukemia (ALL) weren't cured or put into prolonged remission by standard chemotherapy, "there really was no good treatment option," says Marlise Luskin, MD, MSCE, a leukemia specialist at Dana-Farber Cancer Institute.
News
The Power of Plus: Combining Immunotherapy With Other Treatments is Showing Great Promise Against a Variety of Cancers
Even heroes need partners. As researchers are discovering, immunotherapy — the avatar of a new approach to cancer treatment — often works better when paired with other types of therapy.
News
Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent have longer survival than patients treated with the standard targeted drug.